Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 29323

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29323

License Grant
The University hereby grants and Licensee and Affiliates accept, during the term and subject to the terms and conditions of this Agreement a) an exclusive, worldwide, royalty-bearing License to use the Know-How in the territory and within the Fields of Use; and b) an exclusive, royalty-bearing License to University's Patent Rights in the territory to make, use, sell, lease, offer to sell, and import any Licensed Products in the Fields of Use and to practice any Licensed Processes in the Fields of Use.
License Property
Patent Rights
1. Inhibitors Of Serine Protease Activity And Their Use In Methods And Compositions For Treatment Of Bacterial Infections PCT/USO4/27711, filed August 26, 2004.

2. Inhibitors Of Serine Protease Activity And Their Use In Methods And Compositions For Treatment Of Bacterial Infections United States Patent Application US 10/925,051, filed August 26, 2004.

Field of Use
Fields of use treatment of bacterial infections; and all research, studies, testing, preclinical and clinical testing and developments relating to internal, topical or other treatment of bacterial infections, including the treatment of (i) Anthrax, (ii) Mycobacterium Tuberculosis (TB) and other Mycobacteria and (iii) Bacterial Pneumonia, and further including the cutaneous anthrax cream.

IPSCIO Record ID: 26110

License Grant
University hereby grants  a) a non-exclusive License to use the Know-How in the territory and within the Fields of Use; and b) an exclusive License to University's Patent Rights in the territory to make, use, sell, lease, offer to sell, and import any Licensed Products and to practice any Licensed Processes.
License Property
Patent Rights
· U.S. Patent No. 6,846,605 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (related to Case # CU9014H).

· U.S. Patent Application No. 11/044,224 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (Continuation application of Patent No. 6,846,605).

· Provisional Patent Application No. 60/742,191 Alpha-1-antitrypsin inhibition of disease and conditions mediated by binding to cell-associate actin (related to Case # CU1428H).

· Provisional Application No. 60/913,174 Title Compositions and Methods of Use for Alpha­Anti Trypsin Having No Significant Serine Protease Inhibitor Activity (CU1697H US).

· PCT Application No, PCT/US2006/061577 Title Compositions and Methods For Treating Actin-Mediated Conditions (CU1428H).

· U.S. Patent Application No.11/719,200 Compositions and Methods For Treating Actin- Mediated Conditions (CU1428H US1).

Field of Use
Fields of Use use of alpha-1 antitrypsin, and any analogs thereof, including but not limited to synthetic analogs, alpha-1 antitrypsin derivatives, alpha-1 antitrypsin fragments, combinations with alpha-1 antitrypsin and modifications of alpha-1 antitrypsin, for the prevention and/or treatment including prophylaxis of, reduction of and/or reduction of symptoms related to any and all viral infections.

Treatment of all viral infections including, without limitation, any and all mutations, strains, and subtypes, including future mutations, strains, and subtypes of Human Immunodeficiency Virus (HIV) (including any viral infections reasonably and/or previously withheld by the University, when they become available); Human Papilloma Virus (HPV); Herpes Simplex Virus (HSV); Hepacivirus; Pestivirus; Avian influenza virus; Human influenza virus; Murray Valley encephalitis; St. Louis encephalitis.

IPSCIO Record ID: 29360

License Grant
The University granted a nonexclusive, worldwide, License to use the Know-How and  an exclusive License to University’s Patent Rights to make, use, sell, lease, offer to sell, and import any Licensed Products.
License Property
License includes the Patent Rights  â€œInhibitors Of Serine Protease Activity And Their Use In Methods And Compositions For Treatment Of Graft Rejection And Promotion Of Graft Survival” PCT Patent Application filed on June 7, 2006, CU TTO File No. CU1268H and “Methods and Compositions for Treatment of Graft Rejection and Promotion of Graft Survival,” Continuation in part filed on July 22, 2008, CU TTO File No. CU1778H.
Field of Use
Fields of Use is the prevention and treatment of graft rejection and promotion of graft survival.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.